5 Long-term acromegaly and associated cardiovascular complications: a case-based review

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue SUPPL. 1, 2009, Pages

  Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

acromegaly; cardiovascular disease; growth hormone (GH); insulin like growth factor 1 (IGF 1); mortality

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ABDOMINAL DISCOMFORT; ACROMEGALY; ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CASE REPORT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EARLY DIAGNOSIS; GROWTH HORMONE BLOOD LEVEL; HEART HYPERTROPHY; HUMAN; HYPERKINESIA; INSULIN BLOOD LEVEL; LIFE EXPECTANCY; MALE; MITRAL VALVE REGURGITATION; NUCLEAR MAGNETIC RESONANCE SCANNER; STOMACH PAIN; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; HUMANS; INSULIN RESISTANCE; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; TIME FACTORS; TUMOR BURDEN;

EID: 73149124695     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(09)70006-5     Document Type: Article

References (38)

1. Melmed S. Medical progress: Acromegaly. The New England Journal of Medicine 355 (2006) 2558-2573
2. Melmed S., Colao A., Barkan A., et al. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 94 (2009) 1509-1517
3. Melmed S. Acromegaly and cancer: not a problem?. Journal of Clinical Endocrinology and Metabolism 86 (2001) 2929-2934
4. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clinical Endocrinology (Oxford) 69 (2008) 347-358
5. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovascular Research 30 (1995) 825-834
6. Chen D.B., Wang L., and Wang P.H. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sciences 67 (2000) 1683-1693
7. Cittadini A., Ishiguro Y., Strömer H., et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circulation Research 83 (1998) 50-59
8. Freestone N.S., Ribaric S., and Mason W.T. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Molecular and Cellular Biochemistry 163-164 (1996) 223-239
9. Ito H., Hiroe M., Hirata Y., et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87 (1993) 1715-1721
10. Colao A., Ferone D., Marzullo P., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 25 (2004) 102-152
11. Bayes-Genis A., Conover C.A., and Schwartz R.S. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circulation Research 86 (2000) 125-130
12. Juul A., Scheike T., Davidsen M., et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106 (2002) 939-944
13. Vasan R.S., Sullivan L.M., D'Agostino R.B., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Annals of Internal Medicine 139 (2003) 642-648
14. Laughlin G.A., Barrett-Connor E., Criqui M.H., et al. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. Journal of Clinical Endocrinology and Metabolism 89 (2004) 114-120
15. Johnsen S.P., Hundborg H.H., Sørensen H.T., et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. Journal of Clinical Endocrinology and Metabolism 90 (2005) 5937-5941
16. Denti L., Annoni V., Cattadori E., et al. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. American Journal of Medicine 117 (2004) 312-317
17. Bondanelli M., Ambrosio M.R., Onofri A., et al. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. Journal of Clinical Endocrinology and Metabolism 91 (2006) 3928-3934
18. van den Beld A.W., Blum W.F., Pols H.A., et al. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. European Journal of Endocrinology 148 (2003) 627-634
19. Clayton R.N. Cardiovascular function in acromegaly. Endocrine Reviews 24 (2003) 272-277
20. Clayton R.N. New developments in the management of acromegaly. Should we achieve absolute biochemical cure. Journal of Endocrinology 155 Suppl. 1 (1997) S23-S29 discussion S31-S32.
21. Bates A.S., Van't Hoff W., Jones J.M., and Clayton R.N. An audit of outcome of treatment in acromegaly. QJM 86 (1993) 293-299
22. Orme S.M., McNally R.J., Cartwright R.A., and Belchetz P.E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 83 (1998) 2730-2734
23. Rajasoorya C., Holdaway I.M., Wrightson P., et al. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology (Oxford) 41 (1994) 95-102
24. Colao A., Ferone D., Marzullo P., and Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 25 (2004) 102-152
25. Wright A.D., Hill D.M., Lowy C., et al. Mortality in acromegaly. QJM 39 (1970) 1-16
26. Etxabe J., Gaztambide S., Latorre P., et al. Acromegaly: an epidemiological study. Journal of Endocrinological Investigation 16 (1993) 181-187
27. Abosch A., Tyrrell J.B., Lamborn K.R., et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 83 (1998) 3411-3418
28. Swearingen B., Barker II F.G., Katznelson L., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 83 (1998) 3419-3426
29. Melmed S. Acromegaly and cancer: not a problem?. Journal of Clinical Endocrinology and Metabolism 86 (2001) 2929-2934
30. Vitale G., Pivonello R., Lombardi G., et al. Cardiovascular complications in acromegaly. Minerva Endocrinologica 29 (2004) 77-88
31. Lombardi G., Galdiero M., Auriemma R.S., et al. Acromegaly and the cardiovascular system. Neuroendocrinology 83 (2006) 211-217
32. Colao A., Cuocolo A., Marzullo P., et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. Journal of Clinical Endocrinology and Metabolism 86 (2001) 1551-1557
33. Colao A., Marzullo P., Cuocolo A., et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clinical Endocrinology (Oxford) 58 (2003) 169-176
34. Colao A., Cappabianca P., Caron P., et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clinical Endocrinology (Oxford) 70 (2009) 757-768
35. Colao A., Ferone D., Marzullo P., et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 86 (2001) 2779-2786
36. Giustina A., Bonadonna S., Bugari G., et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European Journal of Endocrinology (2009) [Epub ahead of print].
37. Colao A., Pivonello R., Auriemma R.S., et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. European Journal of Endocrinology 157 (2007) 579-587
38. Colao A., Pivonello R., Auriemma R.S., et al. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. Journal of Clinical Endocrinology and Metabolism 93 (2008) 3436-3442